On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.
Luen S, Griguolo G, Nuciforo P, Campbell C, Fasani R, Cortes J, Untch M, Lin S, Savas P, Fox S, Di Cosimo S, Llombart Cussac A, de Azambuja E, Piccart-Gebhart M, Pusztai L, Sotiriou C, Salgado R, Prat A, Loi S. On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. Journal Of Clinical Oncology 2019, 37: 574-574. DOI: 10.1200/jco.2019.37.15_suppl.574.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesBreast cancerPrognostic valuePoor patientsTissue-resident memory cellsEarly-stage HER2Resident memory cellsEarly breast cancerImmune cell subsetsFuture trial designPrediction of pCRHER2 therapyNeoALTTO trialImmune subsetsClinical outcomesClinicopathological variablesF patientsCell subsetsTrial designTreatment changesMultivariate analysisPatientsNeoALTTOHER2EFS